Baird Downgrades Contineum Therapeutics to Neutral, Lowers Price Target to $14

Baird analyst Joel Beatty has downgraded Contineum Therapeutics (NASDAQ: CTNM) from Outperform to Neutral. Additionally, the price target for the stock has been reduced from $19 to $14.